The evolving business model in the biopharmaceutical industry depends on increased productivity in clinical trials. This demands lower-cost, faster and more effective clinical trial processes. These needs encourage biopharmaceutical companies to expand clinical trial programs into emerging regions. In the Middle East, Turkey and North Africa (MENA), the combination of a high population, a low number of current clinical trials and a growing market for biopharmaceuticals makes an appealing region for expanded clinical-research opportunities. Given that MENA’s market for biopharmaceuticals currently outstrips the volume of clinical trials conducted in the region, increasing expectations from regulatory agencies, as well as governments, demand a better balance between these metrics. Based on these drivers and a quantitative analysis of the global market for clinical trials, MENA’s percentage of global clinical trial patient–related R&D spend could increase by a factor of 8-10 in the next decade. To fulfill the technical and staffing needs of such growth, the biopharmaceutical industry will probably rely heavily on contract research organizations (CROs). As a result, the annual CRO share of the clinical trial market in MENA could reach hundreds of millions of dollars in the next 10 years.
About the Author
Vladimir Misik, Ph.D., is Senior Regional Director, Middle East, Clinical Operations at Quintiles and is responsible for clinical development in the Middle East. Vladimir joined Quintiles in 1998 as Business Development Director Central & Eastern Europe (CEE).
Recognizing business opportunities in the emerging Middle East region in 2006, Vladimir spearheaded the expansion of Quintiles clinical operations in the Middle East.
Vladimir has spent 27 years in biopharmaceutical research and development, including 14 years of research in cardiovascular pharmacology and cancer therapy at the U.S. National Cancer Institute, the George Washington University Medical School in Washington, D.C., and Slovak Academy of Sciences, Bratislava. Vladimir holds a Ph.D. in biophysics & pharmacology, and an MS in biophysics and solid state physics. He has authored more than 60 research articles and book chapters in peer-reviewed journals.